Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Interventional Cardiology

Background:

• Estrogen replacement therapy (ERT) is linked to reduced cardiovascular events and improved endothelial function in women.
• The impact of ERT on restenosis rates after percutaneous coronary interventions (PCIs) remains unexamined.

Purpose of the Study:

• To investigate the relationship between estrogen replacement therapy and the rate of restenosis following coronary angioplasty and atherectomy.
• To determine if estrogen use influences restenosis outcomes in women undergoing PCI.

Main Methods:

• A cohort of 204 women from the Coronary Angioplasty Versus Excisional Atherectomy Trial with angiographic follow-up were assessed for menopausal and ERT status.
• Quantitative coronary angiography at 6-month follow-up compared late lumen loss, restenosis rates (>50% stenosis), and other metrics between estrogen users and nonusers.

Main Results:

• Women using estrogen exhibited significantly less late loss in minimal lumen diameter compared to nonusers (-0.13 vs. -0.46 mm, p=0.01).
• Estrogen use was the most significant predictor of reduced late lumen diameter loss (F=13.38, p=0.0006).
• A significant interaction between estrogen use and intervention type was observed; estrogen significantly reduced late loss and restenosis rates in atherectomy patients but had minimal effect after angioplasty.

Conclusions:

• Estrogen replacement therapy shows potential in reducing angiographic measures of restenosis in postmenopausal women post-coronary intervention.
• The beneficial effect of estrogen on restenosis appears more pronounced in women undergoing atherectomy compared to angioplasty.